Atopic Dermatitis Treatment with Dupilumab May Contribute to Acute Mood Episodes in Rare Cases

Strategic Insights -

Studies have shown that dupilumab, a biologic treatment for atopic dermatitis, can be an effective treatment for both resolving skin conditions and reducing the risk of psychiatric comorbidities. However, a recent study has highlighted the potential for dupilumab to contribute to acute mood episodes in rare cases, particularly in patients who are predisposed to psychiatric conditions.

Researchers have reported two cases of patients with atopic dermatitis who experienced acute mood episodes during treatment with dupilumab. Despite showing remarkable improvement in their skin condition and itch, both patients reported recurrent depressive moods after each injection. The researchers concluded that clinicians should exercise caution for emerging or exacerbation of psychiatric conditions during the period from the beginning of dupilumab treatment until the patient achieves stable condition.

Key Takeaways:

  • Dupilumab, a biologic treatment for atopic dermatitis, can be effective in resolving skin conditions and reducing the risk of psychiatric comorbidities.
  • Rare cases of atopic dermatitis patients may experience acute mood episodes during treatment with dupilumab, particularly those with a history of psychiatric conditions.
  • Clinicians should exercise caution when using dupilumab, particularly in patients who are predisposed to psychiatric conditions.
  • Patients should be closely monitored for signs of psychiatric comorbidities during dupilumab treatment.
  • Changing the dosing interval or switching to another systemic treatment may be necessary in some cases to manage psychiatric effects.
  • The impact of dupilumab's systemic effects on rare types of patients who are predisposed to psychiatric conditions requires further study.

Statistics:

  • 2 cases of atopic dermatitis patients experienced acute mood episodes during treatment with dupilumab.
  • 1 patient extended the interval of injection from every 2 weeks to every 4 weeks after 24 injections of dupilumab.
  • 1 patient switched to another systemic treatment due to severe ocular itch after 7 times of administration of dupilumab.
  • 100% of patients in the study reported improvement in their skin condition and itch after treatment with dupilumab.
  • The study was published in Case Reports In Dermatology, Volume 17, Issue 1, pages 409-415.

Sources:

  • "Acute Mood Episodes in Patients of Atopic Dermatitis Treated with Dupilumab: Insights from two Cases." Case Reports In Dermatology, vol. 17, no. 1, 2025, pp. 409-415.
  • Go Sasaki, Sasaki Dermatological Clinic, Iwate, Japan.
  • NewsRx. "Studies from Go Sasaki and Co-Researchers Yield New Data on Atopic Dermatitis (Acute Mood Episodes in Patients of Atopic Dermatitis Treated with Dupilumab: Insights from two Cases)." Psychology & Psychiatry Journal, October 25, 2025, p 1088.